Cancer and glaucoma: A systematic review.

Eur J OphthalmolJun 2, 2026 (epub)
Clinical ResearchOphthalmologyOncology (Medical)

Tammy Si Yue Yim, Titus Hutch Jr Yi Zheng Yim, Kevin Kun Peng Wang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined the relationship between glaucoma and cancer, analyzing 44 studies. It found that 18 studies reported increased glaucoma prevalence in cancer patients, while 15 studies indicated that glaucoma may heighten the risk of complications in intraocular cancers. The review highlights the need for monitoring glaucoma in cancer patients.

Key findings

  • Eighteen studies reported increased glaucoma prevalence among intraocular and non-ocular cancer patients.
  • Fifteen studies suggested that glaucoma increases the risk of regional invasion and metastases in intraocular cancers.
  • Corticosteroids used in cancer therapy were linked to elevated intraocular pressure.

Why it matters

Understanding the interplay between glaucoma and cancer is crucial for clinicians, as it may influence patient management and outcomes. Monitoring glaucoma in cancer patients could help identify complications early and improve overall care.

Source

PubMed · PMID 42228376

Published in Eur J Ophthalmol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.